- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06479174
뇌 건강을 최적화하고 뇌졸중 후 세대 간 혈관 위험 요인을 관리하기 위한 인지 전략 (CHAMPS-TR)
뇌 건강을 최적화하고 뇌졸중 후 세대 간 혈관 위험 요인을 관리하기 위한 인지 전략(세대 간 위험을 위한 CHAMPS)
People living with the cognitive effects of stroke are at risk for recurrent stroke and further cognitive decline. Also problematic is that stroke risk clusters in families and biological family members of people who have ischemic stroke may also be at increased risk of stroke and/or cognitive decline. The primary goal of this study is to test the feasibility of a virtually delivered cognitive strategy training and health coaching program to reduce vascular risk and promote brain health in persons with stroke and their biological family members.
연구 개요
상세 설명
CHAMPS for Transgenerational Risk (TR) (Cognitive strategies for optimizing brain Health And Managing transgenerational vascular risk factors Post-Stroke), a feasibility trial for preventing stroke and improving cognitive outcomes in persons with stroke and their families. Stroke is used as a vector to identify both persons with post-stroke cognitive impairment and dementia (PSCID)and a targeted family member who may be at risk and could benefit from vascular risk reduction intervention. The investigators integrate the concept of a "teachable moment" where health events can lead to behavior change by targeting family members who are stroke-free but may have vascular risk factors putting them at risk for stroke and vascular cognitive impairment (VCI) in the future. Recognizing that people with stroke frequently encounter barriers to community mobility, the proposed trial will be offered virtually to give even those with difficulty accessing the community an equitable opportunity to participate in clinical research.
In this feasibility trial, the investigators will pilot test the CHAMPS-TR intervention which includes vascular risk reduction coaching and a metacognitive problem-solving protocol which contains guided discovery, goal setting, and strategy training. Index persons with stroke and targeted family members (i.e., biological child, younger sibling) who may be at heightened risk for stroke and VCI will receive the CHAMPS intervention which will be delivered remotely. Participants will be split into two arms and either receive the virtual CHAMPS-TR intervention or CHAMPS-TR intervention plus remotely-supervised transcranial Direct Current Stimulation (RS-tDCS) based on eligibility and preference. tDCS is a minimally invasive brain stimulation technique that may augment the effects of cognitive interventions alone. It has strong evidence in stroke rehabilitation and RS-tDCS is a feasible approach in those with stroke and other clinical populations. The overarching goal of this project is to rigorously test the custom-tailored intervention for families impacted by ischemic stroke.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- University of New Mexico Health Sciences Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- primary diagnosis of acute ischemic stroke,
- impairment of cognitive function (score >1 on Quick Executive Interview - telephone screener),
- absence of severe aphasia (score of 0 or 1 on NIH Stroke Scale),
- absence of pre-stroke dementia (client report),
- absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
- absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
- greater than 40 years of age,
- having a potential family member who meets targeted family member criteria,
- eligible for MRI and Remote Supervised-transcranial direct current stimulation (RS-tDCS) if in CHAMPS-TR plus RS-tDCS (e.g., not pregnant; no intracranial metal implants; no skin lesions on target sites for stimulation; no severe cardiopulmonary, renal or hepatic diseases; no pacemakers; no underlying medical reason for not engaging in MRI or tDCS).
The targeted family member will be:
- a minimum of 18 years of age,
- biological kin of person with stroke,
- absence of dementia (client report),
- absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
- absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
- greater than 18 years of age, and
- having a sibling or parent who had an ischemic stroke
Exclusion Criteria:
For all participants:
- not English speaking, reading, and understanding, and
- no access to video-conference software on a computer or smart device
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CHAMPS-TR
Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training. |
Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC). |
|
실험적: CHAMPS TR plus remotely supervised transcranial direct current stimulation (RS-tDCS)
Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training. Persons with stroke will also receive RS-tDCS. |
Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
American Heart Association Life's Essential 8 Metrics
기간: baseline, up to 7 weeks, and up to 24 weeks
|
metric scores for vascular risk; score is calculated on a 0-100 scale where 100 is ideal |
baseline, up to 7 weeks, and up to 24 weeks
|
|
Cardiovascular risk factors, Aging, and Incidence of Dementia (CAIDE)
기간: baseline, up to 7 weeks, and up to 24 weeks
|
Risk profile score for cognitive decline; score is composed of weightings by reference to age, sex, education, systolic blood pressure, BMI, total cholesterol, and physical activity. Scores range from 0-15 with higher scores indicating greater risk. |
baseline, up to 7 weeks, and up to 24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Oral Trail Making Test Part B
기간: baseline and up to 24 weeks
|
Test of mental sequencing and switching; score with total number of seconds to complete up to 300, total number of errors, and total correct |
baseline and up to 24 weeks
|
|
Number Span Test Forward and Backward
기간: baseline and up to 24 weeks
|
Test of working memory; scored with number of correct trials (0-14), and longest span forward (0, 3-9) and longest span backward (0, 2-8). Higher numbers are greater number of correct items. |
baseline and up to 24 weeks
|
|
Multiple Errands Test Home Version
기간: baseline and up to 24 weeks
|
Test of executive function impact on everyday life; total score of 0-14 with higher levels indicating less impairment; additional sub-scores for errors made and strategies used using total scores. |
baseline and up to 24 weeks
|
|
Mark VCID2 Clinical Cognitive Assessment Battery
기간: baseline and up to 24 weeks
|
Test of cognitive impairment and dementia; total scores on all sub-scores for each included measure. |
baseline and up to 24 weeks
|
|
PROMIS Self-Efficacy for Managing Medications
기간: baseline, up to 7 weeks, and up to 24 weeks
|
Test of self efficacy for managing medications; scoring with item-level calibrations using HealthMeasures Scoring Service |
baseline, up to 7 weeks, and up to 24 weeks
|
|
PROMIS Self-Efficacy for Managing Symptoms
기간: baseline, up to 7 weeks, and up to 24 weeks
|
Test of self efficacy for managing symptoms; scoring with item-level calibrations using HealthMeasures Scoring Service |
baseline, up to 7 weeks, and up to 24 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- HRRCID 23-332
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data Sharing Plan
The investigators will share data collected in this project:
At National Scientific Meetings: The investigators expect to share results from the data at two conferences/scientific meetings a year such as the American Congress of Medical Rehabilitation Conference, the RESNA conference, the American Occupational Therapy Conference, and Aging Conferences.
Through Publication in Scientific Journals: the investigators expect to publish 1-2 journal articles a year where data from the proposed project will be shared with no subject identifiers.
Data to be shared includes de-identified: MRI data, feasibility data, self-efficacy scores, vascular risk factor scores, cognitive/executive function scores
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .